

# Resource Summary Report

Generated by NIF on Sep 2, 2026

## EORTC

RRID:SCR\_004070

Type: Tool

---

### Proper Citation

EORTC (RRID:SCR\_004070)

---

### Resource Information

**URL:** <http://www.eortc.org/>

**Proper Citation:** EORTC (RRID:SCR\_004070)

**Description:** An independent pan-European clinical research organization to improve the standards of cancer care through the multidisciplinary multinational efforts of basic scientists and clinicians. The efforts include the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. They also contribute to the development of new drugs and other approaches in partnership with the pharmaceutical industry which is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. The EORTC Network comprises over 300 hospitals and cancer centers in over 30 countries which include some 2,500 collaborators from all disciplines involved in cancer treatment and research. The EORTC Headquarters staff handle some 6,000 new patients enrolled each year in cancer clinical trials, approximately 30 protocols that are permanently open to patient entry, over 50,000 patients who are in follow-up, and a database of more than 180,000 patients. Intergroup collaboration is also promoted to face current challenges of clinical trials aiming at targeted therapies in order to recruit a large number of patients within a reasonable period of time.

**Abbreviations:** EORTC

**Synonyms:** European Organisation for Research and Treatment of Cancer, European Organization for Research and Treatment of Cancer

**Resource Type:** nonprofit organization

**Keywords:** clinical, translational, drug, clinical research organization, drug development, clinical trial

**Related Condition:** Cancer

**Resource Name:** EORTC

**Resource ID:** SCR\_004070

**Alternate IDs:** nlx\_158510, grid.434691.d, Wikidata: Q50376884

**Alternate URLs:** <https://ror.org/04g9wby70>

**Record Creation Time:** 20220129T080222+0000

**Record Last Update:** 20260829T182146+0000

---

## Ratings and Alerts

No rating or validation information has been found for EORTC.

No alerts have been found for EORTC.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 3133 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Brown M, et al. (2026) Minimizing Early-Onset Lymphedema Following Groin Dissection in Metastatic Melanoma. *Annals of surgical oncology*, 33(7), 6737.

Rathgeber IS, et al. (2026) Unraveling assumptions about clinical relevance in patient-reported outcome data : A qualitative study on perspectives of different interest groups. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 34(2), 155.

Borgerding J, et al. (2026) Bridging gaps in care: medical student home visits and their influence on radiation oncology patients. *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]*, 202(7), 722.

Dasgupta A, et al. (2026) Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE). *Radiation oncology (London, England)*, 21(1), 38.

Hendi M, et al. (2026) Psychological and quality of life outcomes associated with multikinase inhibitors versus immune checkpoint inhibitors in advanced hepatocellular carcinoma. *Scientific reports*, 16(1).

Westerdijk K, et al. (2026) Quality of Life and Experiences of Patients with Gastrointestinal Stromal Tumors (GIST) on Imatinib Treatment. *Journal of gastrointestinal cancer*, 57(1).

Pauli N, et al. (2026) Preventive exercise intervention for trismus in head and neck cancer - a randomized study : Preventive exercise intervention for trismus. *Clinical oral investigations*, 30(4).

Noordhof A, et al. (2026) KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation. *The Cochrane database of systematic reviews*, 2(2), CD016054.

Loper M, et al. (2026) Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial. *BMJ open*, 16(4), e112623.

McDonald AM, et al. (2026) Characterizing Cognitive Outcomes Among Long-Term Survivors of Locally Advanced Head and Neck Cancer. *Psycho-oncology*, 35(4), e70441.

Mougeot JC, et al. (2026) Oral dryness related symptoms in radiation-treated head and neck cancer patients: a pilot study of oral microbiome composition and function. *BMC microbiology*, 26(1).

Filis P, et al. (2026) Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial. *ESMO open*, 11(5), 107696.

Tanase-Damian C, et al. (2026) Sexual Health, Quality of Life, and Fertility Counselling in Breast Cancer Survivors Younger than 40 Years. *Medicina (Kaunas, Lithuania)*, 62(6).

??elik S, et al. (2026) Quality of Life and Psychological Factors in Patients with Metastatic Prostate Cancer Receiving Androgen Receptor-Targeted Therapies: A Prospective Cross-Sectional Real-World Study. *Medicina (Kaunas, Lithuania)*, 62(6).

Ben-Arye E, et al. (2026) Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial. *Medical oncology (Northwood, London, England)*, 43(7).

Stockheim J, et al. (2026) Quality of Life After Robotic Abdominal Surgery - A Retrospective Cross-Sectional Study. *Surgical innovation*, 33(3), 205.

Rischin D, et al. (2026) INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(6), 1087.

Bonhof A, et al. (2026) Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study. *JNCI cancer spectrum*, 10(2).

LaBella D, et al. (2026) The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) dataset. *Scientific data*, 13(1).

Lokhorst DN, et al. (2026) Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study. *Haematologica*, 111(3), 918.